Laeeq S, Reghefaoui T, Zahoor H, et al. - In this systematic review, a total of 15 randomized controlled trials with 7,963 participants were analyzed to describe the comparative efficiency of new drugs vs the standard of care methotrexate for rheumatoid arthritis.

• The analysis included baricitinib, filgotinib, peficitinib, infliximab, certolizumab, sarilumab, tocilizumab namilumab, mavrilimumab, golimumab, and CNT06785.

• Better clinical and radiographical results were shown to be conferred by biologic and targeted synthetic disease-modifying drugs combined with methotrexate or as monotherapy, except for CNT 06785 (anti-Interleukin 17A monoclonal antibody).

• Infections continue to be a significant adverse drug reaction of monoclonal antibodies.

• However, findings showed a crucial role of these drugs in adequately managing this disease for patients with severe arthritis.